EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Microbiota in Gut‐Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease

Narendra Kondapalli iD, Venkatesh Katari iD, Kesha K Dalal iD, Sailaja Paruchuri iD, Charles K Thodeti iD

Comprehensive Physiology · 2025-06 · 15 (3)

DOI: 10.1002/cph4.70024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Comprehensive Physiology, online erschienen am 21.06.2025. Verfasst von Narendra Kondapalli und 4 weiteren Autor:innen. Beteiligte Einrichtung: The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Cardiovascular Diseases, Heart. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 247 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, American Heart Association, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emerging evidence highlights the pivotal role of gut microbiota in regulating cardiovascular health and disease. The gut microbiota, a diverse community of microorganisms residing in the gastrointestinal tract, interacts with its host through metabolites, immune modulation, and systemic signaling pathways, collectively shaping cardiovascular physiology. Dysbiosis, or an imbalance in gut microbial composition, has been linked to various cardiovascular diseases (CVDs), including hypertension, heart failure and atherosclerosis. Key microbial metabolites such as short‐chain fatty acids (SCFAs), trimethylamine N‐oxide (TMAO) and lipopolysaccharides (LPS) have been implicated in mechanisms involving endothelial, cardiac fibroblast, cardiomyocyte dysfunction, systemic inflammation, and metabolic dysregulation. This review explores the dynamic interplay between the gut and the heart, focusing on: gut microbiota composition and its alterations in CVD; microbial‐derived metabolites and their mechanistic roles in cardiovascular pathophysiology; pathways linking gut dysbiosis to endothelial, cardiac fibroblast and cardiomyocyte dysfunction, inflammation, and immune responses; and therapeutic opportunities targeting the gut‐heart axis, including dietary interventions, prebiotics, probiotics and emerging microbiota‐based strategies. By unraveling these intricate relationships, we aim to provide a comprehensive understanding of how gut microbiota shape CVD pathophysiology and discuss potential avenues for novel therapeutics in precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeCardiovascular DiseasesHeartHumansAnimalsDysbiosis

Autor:innen und Institutionen

  • The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.

ORCID-Profile: Narendra Kondapalli, Venkatesh Katari, Kesha K Dalal, Sailaja Paruchuri, Charles K Thodeti

Förderung

  • NIH HHS
  • American Heart Association
  • NHLBI NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Kondapalli, N., Katari, V., Dalal, K. K., Paruchuri, S., & Thodeti, C. K. (2025). Microbiota in Gut‐Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease. Comprehensive Physiology, 15(3). https://doi.org/10.1002/cph4.70024

Vancouver

Kondapalli N, Katari V, Dalal KK, Paruchuri S, Thodeti CK. Microbiota in Gut‐Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease. Comprehensive Physiology. 2025;15(3). doi:10.1002/cph4.70024

BibTeX
@article{Kondapalli2025,
  author = {Kondapalli, Narendra and Katari, Venkatesh and Dalal, Kesha K and Paruchuri, Sailaja and Thodeti, Charles K},
  title = {Microbiota in Gut‐Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease},
  journal = {Comprehensive Physiology},
  year = {2025},
  volume = {15},
  number = {3},
  doi = {10.1002/cph4.70024}
}
Kostenlos starten →